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EXPERIMENTAL STUDIES
hc'~_" - ,lr.~mboxane Receptor
myoczAial Infarct Size in Monkeys When Given During Reperfusion
At a Threshold Dose for !Lnp_rDving Reflow During Thrombolysis .
WILLIAM A. SCHUMACHER, ND, GARY J . GROVER, ND
Princeton, New Jersey
The threshold dose of the selective thromboxane receptor
antagonist SQ 30,741 for increasing reflow during throms
bolysis was identified and then evaluated in a model of
myocardial ischenda with reperNsim . In Pundedud cy
snomoigus monkeys, stenotic carotid arteries were occluded
with a platelet-rich thrombus by electrical stimulation and
recanalized with streptokinase (W80 Uhnin inUairwrially
for I h) and heparin (200 tYkg + 120 U/h intravenously for
3 h). Concurrent administration of SQ 30,741 (2 .1 tug/kg +
0.5 mg/kg per h intravenously for 3 h ; n = 4) enhanced the
extent of reflow 174% compared with saline solution (n = 4;
p < 0.05) during the third hour, when lower doses were
ineffective .
This threshold dose was tested in anesthetized African
green monkeys subjected to 90 min of left circumflex
coronary artery occlusion and 5 Ii of reperfusion . SQ
30,741 (n = 8) or saline solution (n =: 11) was administered
2 min before reperfusion and continued throughout reper-
It is now well established that thromboxane A,/prostaglan-
din H2 receptor antagonists have a cardioprotective effect in
vivo when administered during coronary reperfusion after an
ischemic episode . This has been demonstrated by the capac-
ity of structurally dissimilar thromboxane antagonists to
reduce infarct size in dogs (1), cats (2) and rats (3) after a
period of acute coronary artery occlusion and reperfusion .
Overall, these studies suggest that thromboxane A, plays a
deleterious role in experimental myocardial infarction . In
addition to their anti-ischemic actions, thromboxane recep-
tor antagonists are potent antiplatelet agents that generally
have no direct hemodynamic effects (4) . The demonstration
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fusion . The heart was removed on termination of reperfu-
sion and perfused in vitro with Evans blue and triphenyltet-
razolium chloride dyes to stain tissue at risk and infarcted
tissue, respectively . The percent of left ventricle at risk did
not differ between saline- (37 ± 4%) and SQ 39,741-treated
(35 ± 3%) monkeys . In contrast, infarcted tissue expressed
as percent of the left ventricle at risk was less (p < 0 .01) in
monkeys receiving SQ 30,741 (31 ± 2%) than in those
receiving saline solution (49 ± 5%) .
This 36% reduction in infarct size occurred without
significant differences between treatments in hemodynamic
variables and myocardial blood flows (as assessed by radio-
active micros oheres) measured during control, occlusion
and reperfusion intervals. Thus, a dose of SQ 30,74i'tliat
stabilizes reflow after thrombolysis also possesses anti-
ischemic activity when administered only during coronary
reperfusion in monkeys .
(J Am Coll Cardiol 1990;15:883-9)
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that thromboxane receptor antagonists improve reflow dur-
ing thrombolysis in dogs (5,6) and monkeys (7) without
altering systemic arterial pressure is consistent with this
profile of activity .
The combination of an improved blood flow during revas-
cularization and salvage of cardiac tissue during reperfusion
could be efficacious in the treatment of acute myocardial
infarction . Therefore, as a prelude to clinical investigation, it
would be useful to identify a dose of a thromboxane receptor
antagonist that possesses these complementary activities .
The present study was designed to address this topic using a
selective thromboxane receptor antagonist, SQ 30,741 (8,9),
which has a short duration of action that could be advanta-
geous in the critical care setting. All experiments were
performed in anesthetized monkeys for a potentially closer
comparison with humans . We first identified the threshold
dose of SQ 30,741 required to
improve reflow during strep-
tokinase-induced thrombolysis . This dose of antagonist was
then tested for reduction of myocardial infarct size when
0735-1097/90/43
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given only during reperfusion after 90 min of coronary arwi y
occlusion .
Thrombolysis protocol . The experimental preparation is
the same as that described previously (7)
. Seventeen cyno-
molgus male or female monkeys (Macaca fascicularis) (2
.5
to 3.6 kg) were anesthetized with sodium pentobarbital (30
mg/kg intravenously), and the trachea was cannulated to
maintain the airways patent . A PE-50 catheter was placed in
each femoral vein, one for SQ 30,741 and saline infusions,
the other for heparin infusion . A PE-90 catteter was placed
in a femoral artery to record arterial blood pressure with use
of a P23Db pressure transducer (Gould) . The right carotid
artery was isolated over a span of approximately 2 cm and a
calibrated EPI05 or EPI06 electromagnetic flow probe
(Carolina Medical Electronics) was attached to the vessel
. A
streptokinase infusion cannula (27 gauge hypodermic needle
tip attached to tygon tubing) was inserted into the artery
approximately 0.5 cm proximal to the flow probe . A stimu-
lation electrode (5 mm tip of a 25 gauge hypodermic needle
attached to a 30 gauge wire) was inserted 0 .5 cm distal to the
flow probe and adjusted to contact the intimal surface of the
vessel . A 2 mm wide silver clip was placed over the vessel at
the point of electrode insertion and adjusted so that carotk+
artery flow was reduced by approximately 25%. The clip was
not manipulated further during the experiment, and any
monkeys whose reflow exceeded that measured with the
critical stenosis in place were not included in data analysis .
Physiologic variables were monitored continuously on a
model R611 recorder (Sensor Medics) .
Occlusive thrombosis was produced by continuous stim-
ulation with 100 pA of anodal current. On thrombotic
occlusion, the stimulation was terminated and the no-flow
state was observed for 45 min before a I h intraarterial
infusion of streptokinase (680 U/min) was started. intrave-
nous infusions of heparin (200 U/kg + 2 U/min) and admin-
istration of either vehicle (I ml/h 0 .9% saline solution, n = 4)
or SQ 30,741 (1 .0 mg/kg + 0 .1 mg/kg per h, n = 4
; 2 .1 mg/kg
+ 0.25 m
per It, n = 5 ; 2.1 m
+ 0.5 mg/kg per h,
n = 4) was also begun and maintained for 3 h, at which time
the experiment was terminated . Two monkeys were ex-
cluded because hyperemic flow made stability of the stenosis
uncertain, but all others completed the protocol
.
Acute my rdial infarction protocol
. Twenty-one male
or female African green monkeys (Cercopithecus aethiops)
(3
.1 to 7.0 kg) were anesthetized with sodium pentobarbital
(30 mg/kg intravenously) . PE-90 catheters were placed in a
femoral vein for sodium pentobarbital and SQ 30,741 infu-
sions and in a femoral artery to collect blood samples
. A 5F
SPC350 catheter pressure transducer (Millar Instruments)
was inserted into a femoral artery to monitor arterial blood
pressure . The trachea was cannulated, and respiration was
maintained using a model 665 ventilator (Harvard Appara-
tus). The heart was exposed by a left thoracotomy at the
fourth intercostal space, and the left circumflex coronary
artery was isolated proximal to the first marginal branch . A
PE-90 catheter was placed into the left atrium for injection of
141Ce-, 51Cr-, 46Sc- or 85Sr-labeled microspheres (3M) in all
but three monkeys . Myocardial blood flows were measured
by a reference flow method (10) . Arterial blood samples were
obtained anaerobically before each microsphere injection,
and blood gases were determined on a ABL3 analyzer
(Radiometer). Respiration was adjusted to obtain an arterial
Pco2 of 35 to 40 mm Hg and Pot > 60 mm Hg. Arterial blood
pressure, heart rate and lead II electrocardiogram were
recorded continuously on a model 7D polygraph (Grass
Medical Instruments) .
When the preparation had stabilized microspheres were
injected, and within 5 min the coronary artery was occluded
with ar atraumatic microvascular clamp . After 90 min of
occlusion the clamp was released and reperfusion main-
tained for 5 h. Administration of either SQ 30,741 (2 .1
mg/kg + 0 .5 mg/kg per h, n = 9) or vehicle (6.7 ml + 0 .16
ml/min saline solution, n = 12) began 2 min before reperfu-
sion and was maintained throughout reperfusion . Micro-
spheres were also injected after 45 min of occlusion and I h
of reperfusion . At the end of the experiment the areas of the
left ventricle at risk and infarcted areas were determined as
described previously (11), except that the heart was removed
and stained in vitro . Evans blue dye (0 .5%) was perfused in
a retrograde manner through the aorta and used to demar-
cate the area at risk (unstained tissue) . The left circumflex
coronary artery was cannulated with PE-50 tubing and
perfused with a 1% solution of 2,3,5-triphenyltetrazolium
chloride in phosphate-buffered saline solution to measure
nonviable (unstained) and viable tissue (12) . These dyes
were each perfused at a pressure of 120 cm of H2O for 5 min
at 37%. The heart was cut transversely into five or six slices
and both sides of each slice were traced manually onto a
char transparency . Areas were quantitated by computer-
assisted planimetry . Tissue samples (0.5 to 0.8 g) for flows
were taken from the subepicardium and subendocardium at
the center of the ischemic area (most severe infarct and flow
deprivation) and from a nonischemic section . Radioactivity
was measured in tissue and reference blood samples with use
of an Autogamma 8 gamma counter (Beckman Instru-
ments) .
The person conducting the experiment and determining
infarct size was unaware of the treatment administered
.
Cardioversion was performed in each of three monkeys with
a single application of <20 J . One monkey died during
coronary occlusion (saline group) and another was killed (SQ
30,741 group) because of inadequate oxygenation (Po2 < 50
mm Hg), but all others completed the protocol .
Statistical analysis. Data were analyzed using a micro-
computer statistics package (Systat) . Comparisons between
treatment groups were made by t test or, if appropriate, an
analysis of variance . Data collected at multiple time points
were subjected to analysis of variance with repeated mea-
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Figure 1 . Thrombotically occluded carmid arlericti of anesilicti7ed
cynonwigus monkeys (n =
15) were wcanalized with streptokinase
in the preseAce of heparin . The effect of either SQ 30,741 in three
dose schedules or saline on reperfv~ion was Licrinined using the
blood flows averaged over each hour and expressed as percent
maximat flow possible in the flow-limited stenotic vessel
. *p < 0 .05
for SQ 30,741 compared with saline . Data are mean values ± SE .
sures. Mean differences within and between treatment
groups were detected by contrasts . Analysis of covariance
was used to add collateral flow and area at risk as covariants
in testing for treatment effect on infarct size A p < 0 .05
(two-tailed) was required for statistical significance . All data
in the text and figures are expressed as mean values :t SE
Resuk-,
Thrombollysis data. Thrombolytic reflow in the carotid
artery was seen consistently during the I h streptokinase
infusion (15 of 15 monkeys) . The extent of reflow was
determined by measuring area under the carotid blood flow
trace over each hour and converting this to an average flow .
These values were normalized as percent of the maximal
value possible in the flow-limited vessel . Reflow measured in
this manner was unaffected by any dose of SQ 30 .741 (Fig . 1)
during the hour of streptokinase infusion . During the third
hour, only the I I mg/kg loading dose plus the 0.5 mg/kg per
h infusion of SQ 30,741 increased flow . The 2.1 mg/kg + 0.25
n : 6/kg per h dose was effective at 2 h, but its activity had
deteriorated by hour 3 . The I mg/kg + 0.1 mg/kg per h dose
did not differ from the saline solution at any time .
All ononkeys developed spopatineous eyelivalflow varia-
rions consisting of periodic decreases and increases in ca-
rotid blood flow without alterations in arterial blood pres-
sure . The peak and nadir flows detected during these
responses were determined each hour to provide an index of
reperfusion stability (Fig . 2). The treatment groups had
similar peak flows both during and after streptokinase infu-
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Figure 2 . Strcptotdnase (1
It infusion) was administered along with
heparin (3 h infusion) to reopen thrombotically occluded and
slenwic carotid arteries of anesthetized cynomoigus monkeys
. The
effect of either SQ 30
.741 or saline (3 Ii infusions) on the peak and
nadir flows, which were observed during
each hour was determined .
*p < 0.05 for SQ 30 .741 compared with saline . Data are mean values
± SE .
skm
. All animals exhibited a transient peak in carotid blood
flow that at one lime or another was close (95 ± 2% overall)
to the maximum possible in the stertotic vessel . The nadir
blood flows did not differ during the first and second hours
between treatment groups . There was a tendency for im-
provement in nadir flow during the second hour with the two
highest Moss of SQ 30,741, but statistical significance was
not achieved. The 2.1 mg/kg + 0.5 mg/kg per h dose of SQ
30,741 increased nadir flow markedly only during the third
hour, which contributed primarily to the enhanced average
flow that was observed over this interval
.
Rcocch.%sions were observed after recanalization in all
monkeys including those receiving the thromboxane recep-
tor antagonist
. Nevertheless, the average number of occlu-
sive events was significantly reduced by the two highest
doses of SQ 30,741 (Table I ) .
Acute myocardial infarction data . Heart weight was sim-
ilar in saline (29 ± 3 g)- and SQ 30,741 (23 -- I g, p = 0 .10)-
treated monkeys
. `The area of the left ventricle at risk of
infarction also did not differ between these treatment groups
I R6. 3). In contrast,
infarct
size expressed as a percent of
the area of the left ventricle at risk was less (p < 0 .01) with
SQ 30.741 131 ± 2%) than with saline solution (49 ± 5%
Infarct size expressed as percent of total left ventricle was
also lower (p < 0
.051 in monkeys receiving SQ 30,741 (11 ±
17c) compared with those receiving saline solution (21 ±
3%) . The differences in infarct si-e between treatments were
ur
886
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Table 1 .
Effect of SQ 30,741 or Reocclusion During
St re
ptokinase-Induced Thrombolysis in 15
Cynomolgus Monkeys
Proportion of
*p < 0 .05 compared with saline solution by analysis of variance . Data are
mean values ± SE .
also evident (p < 0.05) when an analysis of covariance was
performed using blood flow measured during occlusion in the
ischemic region (collateral flow) as a covariant . The typical
nontransmural infarct observed in these monkeys was not
usually localized to the subendocardium but tended to center
in the midwall with additional involvement of either the
subepicardium or subendocardium . Frequently, a narrow
rim of epicardium remained viable in monkeys from both
treatment groups .
Regional myocardial blood flows in the subepicardium
and subendocardium did not differ between saline and SQ
30,741 groups at any time (Table 2) . This was true for either
the ischemic or nonischemic vascular beds . The collateral
flow measured in the center of the ischemic zone during
occlusion was low in all monkeys . Interestingly, the subepi-
cardium appeared at greater risk than the subendocardium ;
however, this tendency did not reach statistical significance
in either treatment group. Analysis of covariance revealed
that left ventricular infarct size did not vary with collateral
flow (p = 0 .601), but did vary with area at risk (p < 0.001)
and treatment group (p < 0 .05). After I h of reperfusion,
FIgure 3
. Anesthetized African green monkeys were subjected to 90
min of left circumflex coronary artery occlusion and 5 h of reperfu-
sion
. Either SQ 30,741 (2 .t mglkg + 0.5 mg/kg per h
. intravenously)
(n = 8) or saline solution (n = 11) was infused 2 min before and
throughout reperfusion. The tissue at
risk of infarction (AR) is
expressed as percent of left ventricle
(LV) . The left ventricular
infarct is expressed as percent of area at
risk. *p < 0.01 for SQ
30,741 compared with saline solution
. Data are individual and mean
values ± SE .
subepicardial and subendocardial flows had recovered to
essentially control values in both SQ 30,741- and saline-
treated animals .
Analysis ofhemodynamic data did not reveal any differ-
ences in arterial blood pressure, heart r :_te and double
(rate-pressure) product between monkeys receiving SQ
30,741 or saline solution during the course of experiment
(Table 3). Diastolic and systolic blood pressures were de-
creased equally and reproducibly in the saline (-21 ± 6%®
and -17 ± 5%, respectively) ate .''' 1!t 7 ,11 ` 2
a
+
and
-17 ± 4%, respectively) groups at 10 min after occlusion .
On reperfusion, a further reduction in systolic blood pres-
sure was observed only in saline-treated animals, but the
actual values did not differ between treatments . There was a
tendency for heart rate to increase with time so that the
product of heart rate and mean arterial blood pressure did
not deviate greatly over the duration of the experiment .
Discussion
Effects on thrombolysis. Size limitations precluded the
use of the monkey coronary artery ; however, blood flow in
the carotid artery was similar to that found in the canine
coronary artery favored by most other investigators who
study thrombolysis in vivo . Of most importance, the stenotic
carotid artery of the cynomolgus monkey is prone to the
reduced blood flow and reocclusion observed in the canine
coronary artery under similar conditions (5,13) . We previ-
ously found (7) that antagonism of thromboxane receptors in
monkeys primarily enhances reflow between 2 and 3 h after
the start of thrombolysis. Enhancement of reflow during this
interval was a primary objective in achieving our current
goal of identifying a threshold dose of SQ 30,741 for adjunc-
tive use with streptokinase . Continuous infusions were uc :,d
in these experiments because of the short plasma half-life of
SQ 30,741 in monkeys (9.5 ± i.3 min, unpublished data) .
The 2.1 mg/kg loading dose plus a 0 .5 mg/kg per h
intravenous infusion of SQ 30,741 increased blood flow by
174% during the third hour, which is similar to the effect
obtained in our earlier study with 2 mg/kg + 2 mg/kg per h of
SQ 30,741 . There was also an increased nadir flow during the
third hour and a reduction in the average number of reoc-
clusions during the entire period of reperfusion in response
to 2.1 mg/kg + 0.5 mg/kg per h of SQ 30,741 . With a lower
dose of 2.1 mg/kg + 0 .25 mg/kg per h, the improvement in
reflow was lost between 2 to 3 h, and therefore, this infusion
rate was judged insufficient for sustained activity .
Maximal reflow was not influenced by any dose of SQ
30,741, an observation that is consistent with our previous
findings (7) . Carotid artery blood flow recovered to near the
control stenosis-limited level in monkeys from both treat-
ment groups, thus demonstrating the effectiveness of the
thrombolytic regimen. The observation of intermittent re-
ductions in reflow despite the presence of SQ 30,741 sug-
Treatment
Number of
Reocclusions After
Recanalization
Animals
Undergoing
Reocclusion
Saline solution (I ml + I ml/h) 6.5 ± 0.6 4,4
SQ 30,741 (1 .0 mglkg + 0.1 mglkg per h) 5.3 ± 2.4
3/3
SQ 30,741 (2.1 mg/kg + 0.25 mg/kg per h) 2.8 ± 1 .0* 4/4
SQ 30,741 (2 .1 mg/kg + 0.5 mg/kg per h) 1 .8 ± 0.6*
414
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Table 2. Effect of SQ 30,741 on Regional Myocardial Blood Flows During Coronary Artery Occlusion and Reperfusion in African
Green Monkeys
gests that mediators other than thromboxane maintain a
proaggregatory or vasospastic stimulus . Another possibility
is that incomplete thrombolysis limited the restoration of
vessel patency . However, in the original canine version of
this model (13), similar cyclical flow reductions were not
altered by increasing the streptokinase dose after reflow, a
finding that suggests that these responses are not primarily
attributable to insufficient thrombolysis . Mickelson et al .
(14) found that similar responses in stenotic arteries that had
been injured by electrical current were associated with
platelet accumulation and could be abolished by monoclonal
antibodies to the platelet GPllb/llla receptor . Others have
reported improved efficacy in sustaining reflow in recana-
lized arteries by combining antagonists of thromboxane and
serotonin receptors (6) .
The time to repetfusion is one important variable that
was not analyzed because of the large variability encuun-
tered relative to the numbcr of animals studied . To better
detect effects on lysis time, we combined present and
SCHUMACHER ANI3 DROVER
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*p < 0.01 compared with respective control by analysis of variance with repeated pleasures
. There were no
significant
differences between saline and SQ
AWIL All data are mean values ± SE .
previous data (ref. 7 and unpublished observations) for
monkeys treated with the same amount of streptokinase plus
heparin and either vehicle (n = 20) or a loading dose of 2
nag/kg of SQ 30,741 (n = 17) . In this analysis there was a
tendency for shorter times to reperfusion in the presence of
SQ 30.741, but this effect did not attain statistical signifi-
cance (28 ± 5 and 19 ± 3 min, respectively ; p = 0 .126)
Golino et al . (6) also did not detect acceleration in the
time to reperfusion with a tissue plasminogen activator in
canine coronary arteries using a different thromboxane re-
ceptor antagonist unless a serotonergic antagonist was
coadministered . In contrast, Shebuski et al (5) reported
that yet another thromboxane receptor antagonist reduced
the time for clot lysis with a tissue plasminogen activator
in canine coronary arteries by about 65% . Differences
in the species, size and type of artery, method of induc-
ing thrombosis and thrombolytic agent could have con-
tributed to these discrepant results . Overall, the most
reproducible effect of thromboxane receptor antagonism
Table 3. Effect of SQ 30.741 on Hemodynamic Variables During Coronary Artery Occlusion and Reperfusion in 19 African
Green Monkeys
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*p < 001 compared with control and tp < 0
.01 compared with 85 min occlusion by analysis of variance with repeated measures
. There were no significant
differences between saline solution and SQ 30 .741 . All data are mean values ± SE
.
Nonoccluded Region
Occluded Region
Control
45 min After
Occlusion
60 min After
Reperfusion conlroi
45 min After
Occlusion
60 min After
Reperfusion
Subepicardium Iml/min per 100 g)
Saline solution (n = 8 to 9) I03 ± 8
105 ± 12 I 19 ± IS ly ± 10
I ± 1* 170
± 23
SQ MAI (n m 5 0 7) 105 ± 16 133 ± 28
133 ± 37 100 ± 13
2 ± 1* 141 ± 37
Subendocardium (ml/min per 100 g)
Saline (n = 8 to 9) 120 ± 12 126 ± IS 155 ± 19 117 ± 10
5 ± 3* 116 ± 34
SQ 30,741 In 5 to 7) 117 ± 8 121 ± 17
119 ± 21 130 ± 21
6 ± 3* 112 ± 32
Control
Occlusion
Reperfusion
10 min I h 2 h
5 It
45 min 85 min
W min
Systolic blood pressure (mm Hg)
Saline (n = 11)
106 ± 4 88 ± 7* 85 ± 6* 86 ± 5* 76 ± 5t
86 5 85 ± 3 82 ± 3
SQ 30,741 In = 8)
95±6 80±_8*
90±9 89±6 81±_6 89±4
96±6 90±_6
Diastolic blood pressure (mm Hg)
Saline In = 11) 83 = 3
66 ± 7* 64 ± 81 65 ± 8*
56 ± 5t
66
5 67 ± 4 63 ± 3
SQ 30,741 In = 8)
78±_5 63±8"' 70±6
68±5 61±6
68±4 75±6 66±6
Heart rate tbeats!min)
Saline In = ID 161 ± 3() It() ± In
129 ± 11 135 ± 11
137 ± 9 147
	
8 IS :L II
172 ± W
SO 30 .741 In = 8)
148 ± 9 137 ± 16 145 ± 18 151 ± 18
154 ± 12 17 13
176 ± 11 173 ± 10
Rate-pressure product
(beats/min-mm Hg) x 10'
Saline solution In = 11)
14 ± 2 9 ± I
10 ± 2 10 ± I
9 I 11 ± 1
12 1
SQ30
.74l (n= 8) 12±1 10±2
11±2 11±2
11±1 t I
14±I 13±I
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among various studies has been mitigation of the low
flow state or reocclusion, or both subsequent to throm-
bolysis .
Effects on acute myocardial infarction . Experiments were
performed in African green instead of cynomolgus monkeys
because of their increased size and availability . The thresh-
old dose of SQ 30,741 for increasing thrombolytic reflow was
clearly efficacious against reperfusion injury . Infarct size
expressed as percent of the left ventricle at risk was reduced
by 36% when SQ 30,741 was administered immediately
before and throughout reperfusion . A comparable 33% re-
duction in this variable was observed previously (11) when
SQ 30,741 was given only during reperfusion in dogs ex-
posed to the same durations of ischemia and reperfusion .
Saline-treated animals in both studies had 49% of the left
ventricle at risk infarcted, although a slightly higher propor-
tion of the left ventricle was placed at risk by circumflex
artery occlusion in dogs (approximately 47%) compared with
monkeys (approximately 36%) . These results demonstrate
that SQ 30,741 is cardioprotective in both monkeys and
dogs, despite the potential for interspecies variability in the
production or reactivity to thromboxane, or both (15,16) .
SQ 30,741 did not alter arterial blood pressure, heart rate
or the rate-pressure product any any time, a fact that argues
against a primary contribution of hemodynamic factors in
the observed treatment effects on infarct size . There were
also no differences in myocardial blood flow between SQ
30,741- and saline-treated monkeys during the course of the
experiment. In both treatment groups subepicardial and
subendocardial collateral flows were very low in the central
ischemic zone . Ischemia of this severity has also been
described in baboons (17) and is in contrast to the relatively
greater collateral flows that we have routinely observed in
dogs (1,11,18) . Because collateral flows were uniformly low,
they neither correlated with infarct size nor altered the
interpretation of drug effects on infarct size . This was not the
situation for area at risk, where a high correlation with
infarct size was evident in both treatment groups . The equal
recovery of myocardial flows after I h of reperfusion in
monkeys treated with either SQ 30,741 or saline solution
agrees with previous findings in dogs treated during reperfu-
sion only (11) . Administration of SQ 30,741 during both
occlusion and reperfusion has consistently improved suben-
docardial flow during early reperfusion, indicating some
additional benefit in treating before reperfusion (11,18)
.
Mechanisms. The mechanism responsible for the myo-
cardial sparing activity was not addressed in the current
study
. It is unlikely that limitation of thromboxane produc-
tion is important because ischemia-relatcd increases in
thromboxane production during permanent coronary artery
ligation were unaffected by cardioprotective doses of two
structurally dissimilar thromboxane receptor antagonists
(19,20)
. The most obvious mechanism of action would in-
clude blockade of the deleterious responses to thromboxane
JACC Vel . 15, No . 4
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receptor activation, such as vasospasm, platelet activation
or cytotoxicity (21,22) . The exact response, the type of cells
participating and the source of thromboxane remain unclear .
Recent attention has been given (23) to inflammatory reac-
tions mounted by blood elements, especially neutrophils, in
which free radical generation may participate in reperfusion-
associated myocardial injury. Thromboxane receptor antag-
onists reduce neutrophil infiltration into infarcted myocar-
dium during coronary occlusion with (2) or without (19)
reperfusion . This effect may represent either a direct action
on neutrophils or a diminished stimulus for infiltration sec-
ondary to reduced tissue damage by other mechanisms . The
ability of the thromboxane antagonist BM 13,505 to inhibit
neutrophil activation in whole blood ex vivo (24), and also
neutrophil infiltration into rat hindpaws in vivo (2), suggests
a more direct role for thromboxane in neutrophil function .
Summary and clinical utility . We have demonstrated that
SQ 30,741 can be given at a dose that increases reflow during
thrombolysis and also salvages myocardial tissue after acute
ischemia and reperfusion. The combination of anti-ischemic
and thrombolytic-enhancing activities in a single compound
offers the potential advantage of limiting drug interactions .
Descriptions of platelet activation during thrombolytic use in
experimental animals (25) and in humans (26) certainly
support the platelet inhibition as a desirable goal. Unfortu-
nately, this activity may also accentuate bleeding and,
therefore, a short-acting compound like SQ 30,741 might
offer the additional advantage of better hemostatic control .
Regarding the anti-ischemic effects of SQ 30,741, we have
not determined the critical duration of treatment necessary
to reduce ultimate infarct size in monkeys. However, in a
previous study (11) SQ 30,741 was given to dogs during
occlusion and 4 h of reperfusior and reduced infarct size
measured after 24 h . This information, combined with the
observation that thromboxane receptor antagonists salvage
cardiac tissue after 48 h of complete coronary artery occlu-
sion (20), suggests that thromboxane receptor blockade can
result in long-lasting cardioprotective effects .
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